Actinium Pharmaceuticals, Inc. (ATNM) Financials
Annual revenue, profitability and per-share results for Actinium Pharmaceuticals, Inc., as reported in SEC filings.
Revenue • FY2025
$90K
Net income • FY2025
-$33.89M
▲ 11.4%YoY
Diluted EPS • FY2025
$-1.09
▲ 14.2%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $90K | -$33.89M | — | $-1.09 | -$24.68M | -40274.4% | — |
| FY2024 | — | -$38.24M | — | $-1.27 | -$33.08M | — | — |
| FY2023 | $81K | -$48.82M | — | $-1.83 | -$47.49M | -64098.8% | -92.1% |
| FY2022 | $1.03M | -$33.02M | — | $-1.37 | $8.28M | -3311.1% | -10.0% |
Figures as reported in Actinium Pharmaceuticals, Inc.'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a ATNM filing.
Get an email when ATNM files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.